Maynard Um
-
-
-
-
-
-
-
Bicara Therapeutics Inc. (BCAX) Reports Q2 Loss of $0.82
-
-
-
-
-
-
-
Bicara Therapeutics Inc (BCAX) PT Lowered to $46 at Stifel
-
-
-
-
-
-
-
Bicara Therapeutics (BCAX) Reiterated at Market Outperform by Citizens: 'Attractive'
-
-
-
-
-
-
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
-
-
-
-
-
-
FDA grants breakthrough therapy designation to Bicara's cancer drug
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on Bicara Therapeutics Inc (BCAX)
-
-
-
-
-
-
-
Bicara Therapeutics Inc (BCAX) PT Lowered to $41 at H.C. Wainwright
-
443,834 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

